Research programme: corticotropin releasing factor receptor antagonists - Taisho Pharmaceutical/Janssen Pharmaceutica

Drug Profile

Research programme: corticotropin releasing factor receptor antagonists - Taisho Pharmaceutical/Janssen Pharmaceutica

Alternative Names: CRA 0316; CRA 0450; CRA 1000; CRA 1001; CRA 1065; CRA-5626; JNJ-19567470; R 278995

Latest Information Update: 27 Oct 2009

Price : $50

At a glance

  • Originator Janssen L.P.; Taisho Pharmaceutical
  • Class
  • Mechanism of Action Corticotropin releasing factor receptor 1 antagonists; Corticotropin releasing factor receptor 2 antagonists; Corticotropin-releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Anxiety disorders
  • No development reported Major depressive disorder

Most Recent Events

  • 21 Oct 2009 Preclinical pharmacodynamics data in Anxiety disorders presented at the 39th Annual Meeting of the Society for Neuroscience (SfN-2009)
  • 21 Oct 2009 Preclinical development in Anxiety disorders is ongoing in Japan
  • 09 Dec 2005 Data presented at the 35th Annual Meeting of the Society for Neuroscience (SfN-2005) have been added to the Affective disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top